Epidemiology Market Analysis and Reports | France Conference Series

Market Analysis - Epidemiology 2017

Epidemiology Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2015 – 2025

Global Non-Communicable and Communicable Diseases Economic Burden:

Non-Communicable Diseases pose a substantial economic burden and this burden will evolve into a staggering one over the next two decades. With respect to cardiovascular diseases, chronic respiratory diseases, cancers, diabetes and mental health, the macroeconomic simulations suggest a cumulative output loss of US$ 47 trillion over the next two decades. This loss represents 75% of global GDP in 2010 (US$ 63 trillion). It also represents enough money to eradicate two dollar-a-day poverty among the 2.5 billion people in that state for more than half a century. Although high-income countries currently bear the biggest economic burden of NCDs, the developing world, especially middle-income countries, is expected to assume an ever larger share as their economies and populations grow.

Non-communicable diseases have been established as a clear threat not only to human health, but also to development and economic growth. Claiming 63% of all deaths, these diseases are currently the world’s main killer. Eighty percent of these deaths now occur in low- and middle-income countries. Half of those who die of chronic non-communicable diseases are in the prime of their productive years, and thus, the disability imposed and the lives lost are also endangering industry competitiveness across borders.

The evidence gathered is compelling. Over the next 20 years, NCDs will cost more than US$ 30 trillion, representing 48% of global GDP in 2010, and pushing millions of people below the poverty line. Mental health conditions alone will account for the loss of an additional US$ 16.1 trillion over this time span, with dramatic impact on productivity and quality of life. By contrast, mounting evidence highlights how millions of deaths can be averted and economic losses reduced by billions of dollars if added focus is put on prevention.

            Source: Primary research, Government publication, Epidemiology 2017 internal

On the other side deaths from Communicable Diseases in developing countries is once again soaring, not only because of the AIDS epidemic, but because of the emergence of drug-resistant strains of such diseases as TB and malaria. Communicable diseases claim more than 14 million lives a year and account for about 80 percent of the difference in life expectancy between people in rich and poor countries. Rapidly expanding international trade and travel increase the speed of transmission of new disease threats. Research is examining the economic impact of these new health dangers, assessing how some health care services—which are already failing to confront routine problems—can meet new health challenges, and estimating the cost-effectiveness of specific interventions to prevent HIV and malaria infection, treat AIDS, and slow the national and international spread of potentially devastating new epidemics.

Source: Primary research, Government publication, Epidemiology 2017 internal

The epidemiological forecast that in 2015 there were 1,044,022 diagnosed prevalent cases; this is expected to grow to 1,520,469 cases by 2025, at an AGR of 4.56%.

Source: Primary research, Government publication, Epidemiology 2017 internal

Source: Primary research, Government publication, Epidemiology 2017 internal

Global communicable diseases and non-communicable diseases  database provides an interactive, comprehensive, and analytical view of the epidemiological pharmaceutical market in key countries. It covers over 120 indications in 17 therapy areas across key markets, including the US, Japan, France, Germany, Italy, Spain, and the UK. Additional markets, such as Canada, Brazil, India, and China, are covered if their markets are highly relevant to an indication.

Key Players for Global communicable diseases and non-communicable diseases Market:

Global communicable diseases and non-communicable diseases in 2025" to its store providing overview of the risk factors, comorbidities, and global trends for IPF in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the diagnosed incident and diagnosed prevalent cases of IPF segmented by sex, age (in five-year increments beginning at 18 years and ending at =85 years), and severity in these markets.

Worldwide communicable diseases and non-communicable diseases diagnosed incident cases of IPF will increase from 53,139 cases in 2015 to 62,258 cases in 2025, at an Annual Growth Rate (AGR) of 1.72%. The US will have the highest number of diagnosed incident cases of IPF among the 7MM throughout the forecast period, while Spain will have the lowest. The diagnosed prevalent cases of IPF will also increase from 118,943 cases in 2015 to 137,984 cases in 2025, at an AGR of 1.60%. The US will have the highest number of diagnosed prevalent cases of IPF among the 7MM throughout the forecast period, while Spain will have the lowest.Global communicable diseases and non-communicable diseases research focus on the evolutionary epidemiology of HIV, influenza and common bacterial pathogens.

Source: Primary research, Government publication, Epidemiology 2017 internal

We take a unified view of the epidemiology and evolution of pathogens, driven by complex underlying patterns of host-host, host-pathogen and pathogen-pathogen interactions that require careful disentangling. We use a spectrum of tools ranging from simple mathematical models to complex computer simulations, never in isolation, but always interacting with microbiologists, basic medical scientists and public health professionals.

list of communicable diseases Pharmaceutical Companies:

Leading Pharmaceutical Companies working with CDs & NCD’s:

Communicable diseases

Non- communicable diseases

Allergan, Inc.

Becton, Dickinson and Company

Bristol-Myers Squibb Company

Abbott Lab

Alere Inc


The Medicines Company


Achillion Pharmaceuticals


BioCryst Pharmaceuticals


Emergent Biosolutions, Inc


ADMA Biologics Inc

Cardinal Health


Leading Hospitals working in Epidemiological Outbreaks in Paris, France:

Centre Hospitalier Sud Francilien Corbeil-Essonnes,Jean Minjoz Hospital, Besançon,Hôpital des armées, Brest, The French National Cancer Institute, The French Public Health Agency,National Institute of Health and Medical Research (INSERM), Pierre Louis Institute of Epidemiology and Public Health (iPLESP),The International Prevention Research Institute (iPRI, Hôtel-Dieu de Paris Paris, Beaujon Hospital, Clichy, Amiens University Hospital, Amiens, Angers University Hospital, Angers, Central Hospital Bagnols-sur-Cèze, Broussais University Hospital, Paris, Hôpital Européen Georges-Pompidou, Paris, Centre hospitalier universitaire de Caen, Caen, Hôpital Les Broussailles, Cannes, Hôpital d'instruction des armées Percy, Clamart


Source: Primary research, Government publication, Epidemiology 2017 internal

These estimates are calculated with data collected from employers in all industry sectors, all metropolitan and nonmetropolitan areas, and all states and the District of Columbia. The top employment and wage figures are provided above. The percentile wage estimate is the value of a wage below which a certain percent of workers fall. The median wage is the 50th percentile wage estimate--50 percent of workers earn less than the median and 50 percent of workers earn more than the median. Annual wages have been calculated by multiplying the hourly mean wage by a "year-round, full-time" hours figure of 2,080 hours; for those occupations where there is not an hourly wage published, the annual wage has been directly calculated from the reported survey data.

The relative standard error (RSE) is a measure of the reliability of a survey statistic. The smaller the relative standard error, the more precise the estimate.The value is less than .005 percent of industry employment.

Epidemiology Research Funding Glboally:

Source: Primary research, Government publication, Epidemiology 2017 internal

Leading institutions offering Epidemiology Programs in Paris, France:

American College of Epidemiology (ACE) ,American Public Health Association (APHA),American Society for Public Administration (ASPA),Association Médica Argentina (ADMISAL),Association Mexicana de Epidemiología (AMEPID),Association for Health and Environmental Development (AHED), Eygpt, Association for Middle Eastern Public Policy and Administration (AMEPPA), USA, Association of Chinese Epidemiology, Association of University Programs in Health Administration, USA, Australasian Epidemiological Association (AEA),Cambodian Society of Infectious and Tropical Diseases, Epidemics and Pandemics, Cameroon Society of Epidemiology (CaSE),Canadian Society for Epidemiology and Biostatistics (CSEB),Danish Epidemiological Society (DES),Egyptian Society of Epidemiology (ESE),Egyptian Veterinary Association of Epidemiology ,Saudi Epidemiological Association

Epidemiology Association Conference worldwide:

6th International Conference on Epidemiology & Public Health, International Conference on Public Health, International Disease, Health & society Conference, 3rd International Conference on Public Health in Asia, Impact of Environmental Change on Infectious Diseases 2017, International Conference on Women’s and Children’s Health Colombo, ,Fourth International Conference on Health and Medicine Colombo,  22ndSecond International Conference on Ayurveda Traditional Medicine and Medicinal Plants Colombo, Sri Lanka, 26th International Conference on Healthcare & Life-Science Research, MacroTrend Conference on Health and Medicine

Key Universities extending Epidemiology Program in Paris, France:

Ecole Normale Superieure of Electricity (ENS),Université Pierre et Marie Curie (UPMC),University of Paris Sud,Superior School SUPELEC,Sorbonne Paris Cité - Paris Diderot University,Aix Marseille University, Université Montpellier 1 - UM1,Université Nice Sophia Antipolis, University Paris 1 Panthéon Sorbonne, University of Nantes,INSA Lyon,University of Rennes, Cergy-Pontoise University, École Polytechnique, Toulouse School of Economics TSE, Paris Dauphine University


Source: Primary research, Government publication, Epidemiology 2017 internal


This statistics, evidence and experiences needed to launch a more forceful response to the growing threat posed by no communicable and communicable diseases. The report gives particular attention to conditions in developed - and undeveloped countries. With this increasing growth of market the dissemination of knowledge could occur only through international meetings and conferences. 6th International Conference on Epidemiology & Public Health happening in Paris, France would address the recent advancements happening in this field with a series of key Note, Plenary sessions, Workshops, Symposiums and discussions represented by renowned speakers from more than 40 nations.